Sodium zirconium cyclosilicate (ZS-9) treatment in patients with serum potassium >6.5 mEq/L
نویسنده
چکیده
I am writing in regards to an inaccuracy in the recent case report published in the Journal of Community Hospital Internal Medicine Perspectives by Karmacharya et al. (1). The authors had stated that sodium zirconium cyclosilicate (ZS-9) along with patiromer sorbitex calcium (patiromer) has not been studied in patients with serum potassium (K ) concentrations 6.5 mEq/L. However, it should be noted that while it is true that the phase III trial of patiromer did not include patients with serum K 6.5 mEq/L, that is not the case with ZS-9. Specifically, we would like to point out that:
منابع مشابه
Response to Letter
W e thank Dr. Rasmussen for his recent letter expressing concerns about statements made in our article with regard to the efficacy of sodium zirconium cyclosilicate (ZS-9) in patients with serum potassium (K ) concentrations 6.5 mEq/L. Although ZS-9 is certainly one of the potential agents for the treatment of acute hyperkalemia in the future, the HARMONIZE trial (1) was conducted in an outpati...
متن کاملEffect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.
IMPORTANCE Hyperkalemia is a common electrolyte abnormality that may be difficult to manage because of a lack of effective therapies. Sodium zirconium cyclosilicate is a nonabsorbed cation exchanger that selectively binds potassium in the intestine. OBJECTIVE To evaluate the efficacy and safety of zirconium cyclosilicate for 28 days in patients with hyperkalemia. DESIGN, SETTING, AND PARTIC...
متن کاملMaintenance of serum potassium with sodium zirconium cyclosilicate (ZS‐9) in heart failure patients: results from a phase 3 randomized, double‐blind, placebo‐controlled trial
AIMS Hyperkalaemia in heart failure patients limits use of cardioprotective renin-angiotensin-aldosterone system inhibitors (RAASi). Sodium zirconium cyclosilicate (ZS-9) is a selective potassium ion trap, whose mechanism of action may allow for potassium binding in the upper gastrointestinal tract as early as the duodenum following oral administration. ZS-9 previously demonstrated the ability ...
متن کاملCharacterization of Structure and Function of ZS-9, a K+ Selective Ion Trap
Hyperkalemia, a condition in which serum potassium ions (K+) exceed 5.0 mmol/L, is a common electrolyte disorder associated with substantial morbidity. Current methods of managing hyperkalemia, including organic polymer resins such as sodium polystyrene sulfonate (SPS), are poorly tolerated and/or not effective. Sodium zirconium cyclosilicate (ZS-9) is under clinical development as an orally ad...
متن کاملA phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient
Hyperkalemia contributes to significant mortality and limits the use of cardioprotective and renoprotective renin-angiotensin-aldosterone blockers. Current therapies are poorly tolerated and not always effective. Here we conducted a phase 2 randomized, double-blind, placebo-controlled dose-escalation study to assess safety and efficacy of ZS-9. This oral selective cation exchanger that preferen...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 5 شماره
صفحات -
تاریخ انتشار 2015